CD8A and non-small cell lung carcinoma: One study demonstrated that EGFR-TKI treatment was associated with changes in the TIME in CD8+ TIL density and PD-L1 expression level [75], and that EGFR-TKI could down-regulate PD-L1 in EGFR mutant NSCLC was confirmed in one previous study [76].